Advertisement

Topics

NICE recommends kidney cancer drug “likely to be less effective” than current treatments after price deal

11:29 EST 15 Feb 2018 | British Medical Journal

The National Institute for Health and Care Excellence (NICE) has recommended tivozanib as an option for treating adults with previously untreated advanced renal cell carcinoma, after the manufacturer...

Original Article: NICE recommends kidney cancer drug “likely to be less effective” than current treatments after price deal

NEXT ARTICLE

More From BioPortfolio on "NICE recommends kidney cancer drug “likely to be less effective” than current treatments after price deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...